Trial Profile
Multi-center, randomized, open-label, two-parallel arm, intervention trial comparing DPP-IV inhibitor Vildagliptin with Glibenclamide (Glyburide) in achieving and maintaining good blood glucose control in type 2 diabetic patients in treatment failure with Metformin alone
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2012
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Nov 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 02 Jun 2011 New trial record